Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-TIMI 28
NCT00714961Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2003
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing Clopidogrel + ASA with Placebo + ASA (2 arms). Primary endpoints: Composite of occluded infarct-related artery, death, or recurrent MI at 8 days and Thrombolysis In Myocardial Infarction Major Bleeding at 30 days. Started Feb 2003; status: completed.
02
Drugs
clopidogrel
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00714961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00714961.